<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20211017052786N4</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2022-07-11</date_registration>
      <primary_sponsor>Ghoum University of Medical Sciences</primary_sponsor>
      <public_title>Comparison of the effect of different doses of intrathecal Ropivacaine in surgery</public_title>
      <acronym></acronym>
      <scientific_title>Comparing the Effect of Four Different Doses of Intrathecal Isobaric Ropivacaine on Patients Undergoing Elective Infra-umbilical Surgeries</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2022-06-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>140</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/64308</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: In this study, 140 patients undergoing umbilical cord surgery will be randomly divided into four groups of 35 patients. Random assignment of patients to four groups is based on block method. Each block will be selected at random. Block Randomization is done using dice. Throwing the dice will be done enough to complete the assignment of patients to treatment groups. The size of the block is 8 and we will have different and random combinations of AABBCCDD. The selection of each block will be random to complete the allocation of patients to treatment groups with four different doses. Assignment of treatment to groups A, B, C and D will also be based on accident, Blinding description: This study is a double-blind randomized clinical trial (RCT) in which the participating patients, specialist assistant and surgeon do not know the type of dose assignment to the group.</study_design>
      <phase>2</phase>
      <hc_freetext>Spinal anesthesia using ropivacaine.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group 1: Candidate patients for below-umbilical surgery for spinal anesthesia receive 4 ml of 0.5% Ropivacaine with chemical formula (C17H26N2O) equivalent to 20 mg intra-cerebrospinal fluid (CSF). Intervention 2: Intervention group 2: Candidate patients for below-umbilical surgery for spinal anesthesia receive 4.5 ml of Ropivacaine  0.5% with chemical formula (C17H26N2O) equivalent to 22.5 mg intra-cerebrospinal fluid (CSF). Intervention 3: Intervention group 3: Candidate patients for below-umbilical surgery for spinal anesthesia receive 5 ml of 0.5% Ropivacaine with chemical formula (C17H26N2O) equivalent to 25 mg intra-cerebrospinal fluid (CSF). Intervention 4: Intervention group 4: Candidate patients for below-umbilical surgery for spinal anesthesia receive 5.5 ml of Ropivacaine  0.5% with chemical formula (C17H26N2O) equivalent to 27.5 mg intra-cerebrospinal fluid (CSF).</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>No - There is not a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for not sharing IPD is The data are specific to the present study</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Amir Hossein Moradi Rafigh</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No. 46, 32th Ave., Keshavarz Shomali Blvd.</address>
        <city>Qom</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>3715178817</zip>
        <telephone>+98 25 3885 6440</telephone>
        <email>Amirmmr287@gamil.com</email>
        <affiliation>Ghoum University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Fatemeh Gghannadi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No. 46, 32th Ave., Keshavarz Shomali Blvd.</address>
        <city>Qom</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>3715178817</zip>
        <telephone>+98 25 3885 6440</telephone>
        <email>Amirmmr287@gmail.com</email>
        <affiliation>Ghoum University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Iranian race
Patients with American Stroke Association (ASA) grade 1, 2
Umbilical cord surgeries
Age over 18 and under 65 years</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>65 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Allergy to amide drugs
Pregnancy
History of substance abuse
Heart rate less than 60 beats per minute at rest</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>T88.5</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Other complications of anesthesia</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Treatment - Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group 1: Candidate patients for below-umbilical surgery for spinal anesthesia receive 4 ml of 0.5% Ropivacaine with chemical formula (C17H26N2O) equivalent to 20 mg intra-cerebrospinal fluid (CSF).</i_keyword>
      <i_keyword>Intervention group 2: Candidate patients for below-umbilical surgery for spinal anesthesia receive 4.5 ml of Ropivacaine  0.5% with chemical formula (C17H26N2O) equivalent to 22.5 mg intra-cerebrospinal fluid (CSF).</i_keyword>
      <i_keyword>Intervention group 3: Candidate patients for below-umbilical surgery for spinal anesthesia receive 5 ml of 0.5% Ropivacaine with chemical formula (C17H26N2O) equivalent to 25 mg intra-cerebrospinal fluid (CSF).</i_keyword>
      <i_keyword>Intervention group 4: Candidate patients for below-umbilical surgery for spinal anesthesia receive 5.5 ml of Ropivacaine  0.5% with chemical formula (C17H26N2O) equivalent to 27.5 mg intra-cerebrospinal fluid (CSF)..</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Levels of sensory and motor block. Timepoint: In minutes 15,10,8,8,6,4,2. Method of measurement: Motor nerves using voice commands for the patient and Pinprick of skin to observe the sensory nerve response.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Ghoum University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2022-06-19</approval_date>
        <contact_name>Ethics Committee of QOM University of Medical Sciences</contact_name>
        <contact_address>No.10, 13th Ave., Emam Street. Qom Ghoum Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
